Seattle Genetics is staffing up with eyes on a big year

Seattle Genetics ($SGEN) is looking to recruit roughly 100 new workers throughout its operations, the company said, accelerating its pipeline of armed antibody candidates. The biotech is dialing up its R&D budget in 2015, executives told the Seattle Business Journal, following through on partnering agreements and pushing early-stage candidates into clinical trials. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.